临床试验设计科学审查及其信息量的成熟度模型
文章指出,临床试验常因设计审查不足而无法产生确定性结果,伦理与监管审查不覆盖设计与生物统计,资助方也缺乏科学设计审查标准。作者提出一个用于临床试验方案科学设计审查的成熟度模型,包含11个过程领域和5个成熟度等级,共55个过程领域等级,每个等级配有描述,以帮助资助方在资助后审查中提升试验信息量并改善投资回报。
要点
- 临床试验常因设计审查不足而无法产生确定性结果。
- 伦理与监管审查不覆盖试验设计与生物统计,资助方缺乏科学设计审查标准。
- 作者提出的成熟度模型包含11个过程领域和5个成熟度等级。
核心结论
- 该成熟度模型可为资助后试验审查的后续投资提供规范性指导,重点在于提升信息量。
- 传统资助前同行评议对试验设计审查能力有限,尤其缺乏详细的生物统计与方法学审查。
- 部分非产业资助方已基于此类项目范例开始探索或投资受资助者方案的资助后审查项目。
研究设计与样本
- 本文提出一个用于临床试验方案科学设计审查的成熟度模型,包含11个过程领域和5个成熟度等级。
- 每个过程领域等级均配有描述,构成朝向优化状态的连续体,以改善试验方案在失败风险或无信息量方面的表现。
主要发现
- 成熟度模型是知识转移的有用工具,可帮助在新领域发展能力或对现有领域进行自我评估。
- 该模型共包含55个过程领域等级,每个等级配有描述。
- 伦理与监管审查已投入并标准化,但研究常未完成或未能提供确定性结果。
关键数值与推荐
- 模型包含11个过程领域和5个成熟度等级,共55个过程领域等级。
临床怎么用
- 希望履行受托责任和使命目标的资助方可使用所述模型加强相关工作,以支持试验参与者承诺和更快治愈。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Informativeness, in the context of clinical trials, defines whether a study's results definitively answer its research questions with meaningful next steps. Many clinical trials end uninformatively. Clinical trial protocols are required to go through reviews in regulatory and ethical domains: areas that focus on specifics outside of trial design, biostatistics, and research methods. Private foundations and government funders rarely require focused scientific design reviews for these areas. There are no documented standards and processes, or even best practices, toward a capability for funders to perform scientific design reviews after their peer review process prior to a funding commitment. MAIN BODY: Considering the investment in and standardization of ethical and regulatory reviews, and the prevalence of studies never finishing or failing to provide definitive results, it may be that scientific reviews of trial designs with a focus on informativeness offer the best chance for improved outcomes and return-on-investment in clinical trials. A maturity model is a helpful tool for knowledge transfer to help grow capabilities in a new area or for those looking to perform a self-assessment in an existing area. Such a model is offered for scientific design reviews of clinical trial protocols. This maturity model includes 11 process areas and 5 maturity levels. Each of the 55 process area levels is populated with descriptions on a continuum toward an optimal state to improve trial protocols in the areas of risk of failure or uninformativeness. CONCLUSION: This tool allows for prescriptive guidance on next investments to improve attributes of post-funding reviews of trials, with a focus on informativeness. Traditional pre-funding peer review has limited capacity for trial design review, especially for detailed biostatistical and methodological review. Select non-industry funders have begun to explore or invest in post-funding review programs of grantee protocols, based on exemplars of such programs. Funders with a desire to meet fiduciary responsibilities and mission goals can use the described model to enhance efforts supporting trial participant commitment and faster cures.
引用
- Dolley S, Norman T, McNair D, et al. A maturity model for the scientific review of clinical trial designs and their informativeness. Trials. 2024. PMID: 38641848. doi:10.1186/s13063-024-08099-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。